Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced it has surpassed five million Motiva devices in market across more than 100 countries worldwide.

The medical technology company, which focuses on breast aesthetics and reconstruction, reached this milestone three years after announcing it had exceeded three million devices. Chief Executive Officer Peter Caldini stated the company has maintained over 25% revenue growth in 2025, continuing into 2026.

The growth has been driven by Motiva's entry into the United States market and global expansion of the company's minimally invasive platform. Caldini attributed the milestone to sustained global adoption of the company's breast aesthetics and reconstruction solutions.

Dr. Mark Epstein, a board-certified plastic surgeon in Hauppauge, New York, reported significant practice growth using the company's products. In the first quarter of 2026, 56 patients selected the Preservé minimally invasive procedure at his practice. Epstein completed 90 cases in the last six months and has scheduled 50 Preservé cases for the second quarter.

The Preservé procedure is priced 30% higher than standard Motiva breast augmentation, according to Epstein. The procedure avoids general anesthesia, preserves native breast tissue and chest muscles, and supports faster recovery.

Establishment Labs manufactures its products at two facilities in Costa Rica under ISO13485:2024 and FDA 21 CFR 820 standards. The company's product portfolio includes devices for breast health, aesthetics, and reconstruction, supported by over 200 patent applications across 20 patent families and more than 100 scientific studies.